# US 2017/0253579 A1 · Substituted pyrroles active as kinases inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0253579 A1
- Document ID: US20170253579A1
- Status: Published application
- Kind: A1
- Application number: 15/599,025
- Filed: 2017-05-18
- Published: 2017-09-07
- Earliest claimed: 2012-08-02
- Assignees: Nerviano Medical Sciences S.R.L.
- Applicants: NERVIANO MEDICAL SCIENCES S.r.l.
- Inventors: Maria Gabriella Brasca; Simona Bindi; Marina Caldarelli; Marcella Nesi; Sten Christian Orrenius; Achille Panzeri
- Web page: https://patentgrep.com/patent/US20170253579A1

## CPC

- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/52: Purines, e.g. adenine
- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 471/04: Ortho-condensed systems
- C07D 473/00: Heterocyclic compounds containing purine ring systems
- C07D 487/04: Ortho-condensed systems
- C07F 5/04: Esters of boric acids
- C07F 7/083: {Syntheses without formation of a Si-C bond}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The present invention relates to substituted pyrrole compounds which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular Jak family kinases. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such compounds or the pharmaceutical compositions containing them.

## Claims

### Claim at position 1

-30. (canceled)

### Claim 31

A compound of formula (I):
wherein:
Ring W is a pyrrole;
R1 is a substituted aryl;
R2 is CN or CONR6R7 wherein R6 and R7 are independently hydrogen or an optionally substituted group selected from straight or branched C1-C6 alkyl, straight or branched C2-C6 alkenyl, straight or branched C2-C6 alkynyl, C3-C7 cycloalkyl, cycloalkyl-alkyl, aryl, aryl-alkyl, heteroaryl, heteroaryl-alkyl, heterocyclyl and heterocyclyl-alkyl, or R6 and R7, taken together with the nitrogen atom to which they are bonded, may form an optionally substituted 5 to 7 membered heterocyclyl group optionally containing one additional heteroatom selected from N, O and S;
R3 is hydrogen, halo or an optionally substituted group selected from straight or branched C1-C6 alkyl, C3-C7 cycloalkyl, cycloalkyl-alkyl, heterocyclyl and heterocyclyl-alkyl;
R4 is an optionally substituted heteroaryl group selected from
wherein:
R8 is hydrogen or an optionally substituted group selected from straight or branched C1-C6 alkyl, straight or branched C2-C6 alkenyl, straight or branched C2-C6 alkynyl, C3-C7 cycloalkyl, cycloalkyl-alkyl, aryl, aryl-alkyl, heteroaryl, heteroaryl-alkyl, heterocyclyl and heterocyclyl-alkyl, COR9, CONR10R11 and SO2R12,
wherein:
R9 is a group optionally substituted selected from straight or branched C1-C6 alkyl, straight or branched C2-C6 alkenyl, straight or branched C2-C6 alkynyl, C3-C7 cycloalkyl, cycloalkyl-alkyl, aryl, aryl-alkyl, heteroaryl, heteroaryl-alkyl, heterocyclyl and heterocyclyl-alkyl;
R10 and R11 are independently hydrogen or an optionally substituted group selected from straight or branched C1-C6 alkyl, straight or branched C2-C6 alkenyl, straight or branched C2-C6 alkynyl, C3-C7 cycloalkyl, cycloalkyl-alkyl, aryl, aryl-alkyl, heteroaryl, heteroaryl-alkyl, heterocyclyl and heterocyclyl-alkyl, or R10 and R11, taken together with the nitrogen atom to which they are bonded, may form an optionally substituted 5 to 7 membered heterocyclyl group optionally containing one additional heteroatom selected from N, O and S;
R12 is a group optionally substituted selected from straight or branched C1-C6 alkyl, straight or branched C2-C6 alkenyl, straight or branched C2-C6 alkynyl, C3-C7 cycloalkyl, cycloalkyl-alkyl, aryl, aryl-alkyl, heteroaryl, heteroaryl-alkyl, heterocyclyl and heterocyclyl-alkyl;
R5 is hydrogen, halo or an optionally substituted group selected from straight or branched C1-C6 alkyl, C3-C7 cycloalkyl, cycloalkyl-alkyl, heterocyclyl and heterocyclyl-alkyl;
or a pharmaceutically acceptable salt thereof.

### Claim 32 (depends on 31)

A compound of the formula (I), as defined in claim 31, wherein R2 is CN.

### Claim 33 (depends on 31)

A compound of the formula (I), as defined in claim 31, wherein R2 is CONR6R7, wherein R6 and R7 are as defined in claim 31.

### Claim 34

A compound or a pharmaceutically acceptable salt thereof which is selected from the group consisting of:
1-(5-Chloro-2-methylphenyl)-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-2-carbonitrile (compd 63);
1-(5-Chloro-2-ethylphenyl)-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-2-carbonitrile (compd 68);
1-[2-Chloro-5-(trifluoromethyl)phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-2-carbonitrile (compd 72);
3-(5-Chloro-2-methylphenyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-2-carboxamide (compd 123);
3-(5-Chloro-2-ethylphenyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-2-carboxamide (compd 124);
3-[2-Ethyl-5-(trifluoromethyl)phenyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-2-carboxamide (compd 125);
3-(5-Chloro-2-methylphenyl)-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-2-carboxamide (compd 129);
3-(5-Chloro-2-ethylphenyl)-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-2-carboxamide (compd 130);
3-[2-Ethyl-5-(trifluoromethyl)phenyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-2-carboxamide (compd 131);
2-(5-Chloro-2-methylphenyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-H-pyrrole-3-carboxamide (compd 191);
2-(5-Chloro-2-ethylphenyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-3-carboxamide (compd 199);
2-[2-Chloro-5-(trifluoromethyl)phenyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-3-carboxamide (compd 206);
2-[2-Methyl-5-(trifluoromethyl)phenyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-3-carboxamide (compd 213);
2-[2-Ethyl-5-trifluoromethyl)phenyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-3-carboxamide (compd 220);
1-(5-Chloro-2-methylphenyl)-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-2-carboxamide (compd 229);
1-(5-Chloro-2-methylphenyl)-4-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-2-carboxamide (compd 234);
1-(5-Chloro-2-ethylphenyl)-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-2-carboxamide (compd 237);
1-(5-Chloro-2-ethylphenyl)-4-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-2-carboxamide (compd 241);
1-[2-Chloro-5-(trifluoromethyl)phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-2-carboxamide (compd 244);
1-[2-Chloro-5-(trifluoromethyl)phenyl]-(9H-purin-6-yl)-1H-pyrrole-2-carboxamide (compd 245);
1-[2-Chloro-5-(trifluoromethyl)phenyl]-4-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1H-pyrrole-2-carboxamide (compd 246);
4-(5-Chloro-2-methylphenyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-3-carboxamide (compd 270);
2-(5-Chloro-2-ethylphenyl)-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-3-carboxamide (compd 303);
2-[2-Methyl-5-(trifluoromethyl)phenyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-3-carboxamide (compd 318); and
2-[2-Ethyl-S-trifluoromethyl)phenyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-3-carboxamide (compd 323).

### Claim 35 (depends on 31)

A process for preparing a compound of formula (I) as defined in claim 31 or the pharmaceutically acceptable salts thereof wherein the process comprises:
Step 1: reaction of a derivative of formula (II)
wherein R1 and R3 are as defined in claim 31 and PG is a protecting group such as benzenesulfonyl with 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxyborolane;
alternatively:
Step 1a: reaction of a halo derivative of formula (III)
wherein R1, R3 are as defined above, X is halogen, and PG is a protecting group such as 2-(trimethylsilyl)ethoxymethyl, tert-butyloxycarbonyl,
with 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxyborolane;
Step 2: metal-catalyzed coupling reaction of the resultant compound of formula (IV)
wherein R1, R3 are as defined above and PG is a protecting group such as 2-(trimethylsilyl)ethoxymethyl, tert-butyloxycarbonyl, benzenesulfonyl with a halo derivative of formula (V)
R4-x (V)
wherein R4 is as defined in claim 31 and X is halogen;
Step 3: deprotection of the resultant compound of formula (VI)
wherein R1, R3, R4 are as defined above and PG is a protecting group such as 2-(trimethylsilyl)ethoxymethyl, tert-butyloxycarbonyl, benzenesulfonyl to give a compound of formula (Ia)
wherein R1, R3, R4 are as defined above, R2 is CN and R5 is hydrogen;
alternatively
Step 4: reaction of a derivative of formula (VII)
wherein R1 and R3 are as defined above and PG is a protecting group such as benzenesulfonyl with 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxyborolane;
Step 5: metal-catalyzed coupling reaction of the resultant compound of formula (VIII)
wherein R1 and R3 are as defined above and PG is a protecting group such as benzenesulfonyl with a halo derivative of formula (V), as defined above;
Step 6: hydrolysis under basic conditions of the resultant carboxylic ester of formula (IX)
wherein R1, R3, R4 and PG are as defined above;
Step 7: amidation of the resultant carboxylic acid of formula (X)
wherein R1, R3 and R4 are as defined above, through reaction with an amine derivative of formula (XI)
NHR6R7 (XI)
wherein R6 and R7 are as defined in claim 31, to give a compound of formula (Ia)
wherein R2 is CONR6R7, R5 is hydrogen, R1, R3, R4, R6 and R7 are as defined above;
alternatively
Step 8: reaction of a halo derivative of formula (XII)
wherein R1, R3 and R5 are as defined above and X is halogen with 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxyborolane;
Step 9: metal-catalyzed coupling reaction of the resultant compound of formula (XIII)
wherein R1, R3 and R5 are as defined above, with a halo derivative of formula (V), as defined above, to give a compound of formula (Ib)
wherein R1, R3, R4 and R5 are as defined above and R2 is CN;
alternatively
Step 10: reaction of a derivative of formula (XI)
wherein R1, R3 and R5 are as defined above, with a halo derivative of formula (V), as defined above, in the presence of a base or metal-catalyzed to give a compound of formula (Ic)
wherein R1, R3, R4 and R5 are as defined above and R2 is CN;
alternatively
Step 11: reaction of a derivative of formula (XV)
wherein R1 and R5 are as defined above and PG is a protecting group such as benzenesulfonyl with 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxyborolane;
Step 12: metal-catalyzed coupling reaction of the resultant compound of formula (XVI)
wherein R1 and R5 are as defined above and PG is a protecting group such as benzenesulfonyl with a halo derivative of formula (V), as defined above;
Step 13: hydrolysis under basic conditions of the resultant carboxylic ester of formula (XVII)
wherein R1, R4 and R5 are as defined above and PG is a protecting group;
Step 14: amidation of the resultant carboxylic acid of formula (XVIII)
wherein R1, R4 and R5 are as defined above, through reaction with an amine derivative of formula (XI), as defined above, to give a compound of formula (Id)
wherein R1, R2, R4 and R5 are as defined above and R3 is hydrogen;
alternatively
Step 15: reaction of a halo derivative of formula (XIX)
wherein R1, R3 and R5 are as defined above, PG is a protecting group such as tert-butyloxycarbonyl and X is halogen with 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxyborolane;
Step 16: metal-catalyzed coupling reaction of the resultant compound of formula (XX)
wherein R1, R3 and R5 are as defined above and PG is a protecting group such as tert-butyloxycarbonyl, with a halo derivative of formula (V), as defined above;
Step 17: deprotection of the resultant compound of formula (XXI)
wherein R1, R3, R4 and R5 are as defined above and PG is a protecting group such as tert-butyloxycarbonyl;
Step 18: reaction of the resultant compound of formula (XXII)
wherein R1, R3, R4 and R5 are as defined above, with an amine derivative of formula (XI), as defined above, in the presence of triphosgene, to give a compound of formula (Ie)
wherein R2 is CONR6R7 and R1, R3, R4, R5, R6 and R7 are as defined above;
optionally converting a compound of the formula (I) into another different compound of the formula (I), and, if desired, converting a compound of the formula (I) into a pharmaceutically acceptable salt thereof or converting a salt into the free compound (I).

### Claim 36 (depends on 31, 35)

A process for preparing a compound of formula (I) according to claim 35, wherein the optional conversion of a compound of formula (I) into another compound of formula (I) is carried out by one or more of the following reactions:
conv.1) converting a compound of the formula (I), wherein R2 is CN, into the corresponding compound of formula (I), wherein R2 is CONH2, by hydrolising in acidic conditions,
conv.2) converting a compound of the formula (I), wherein R2 is CONH2, into the corresponding compound of formula (I), wherein R2 is CONR6R7 wherein R6 and R7 are as defined in claim 31 but not both hydrogen
by hexaustive tert-butoxycarbonylation of a compound of the formula (I), treatment with an amine derivative of formula (XXIII)
NHR6R7 (XXIII)
wherein R6 and R7 are as defined above but not both hydrogen and deprotection of tert-butoxycarbonyl protecting groups;
conv.3) converting a compound of the formula (Ia), wherein R5 is hydrogen or (Id) wherein R3 is hydrogen, into the corresponding compound of formula (Ia) or (Id), wherein R5 or R3 respectively is an optionally substituted group selected from straight or branched C1-C6 alkyl, C3-C7 cycloalkyl, cycloalkyl-alkyl, heterocyclyl and heterocyclyl-alkyl,
by treatment with optionally substituted alkyl halide of the formula R5-X (XXIV) or R3-X (XXV), wherein R5 or R3 respectively is as defined above and X is halogen.

### Claim 37 (depends on 31)

A method for treating a disease caused by and/or associated with a dysregulated protein kinase activity which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I) as defined in claim 31.

### Claim 38 (depends on 37)

The method according to claim 37 for treating a disease caused by and/or associated with a dysregulated JAK family kinases activity.

### Claim 39 (depends on 37)

The method according to claim 37 wherein the mammal in need thereof is a human.

### Claim 40 (depends on 37)

The method according to claim 37 wherein the disease is selected from the group consisting of cancer, cell proliferative disorders, viral infections, immune-related disorders, neurodegenerative disorders, cardiovascular diseases and bone related diseases.

### Claim 41 (depends on 40)

The method according to claim 40 wherein the cancer is selected from the group consisting of carcinoma such as bladder, breast, brain, colon, kidney, liver, lung, including small cell lung cancer, head and neck, esophagus, gall-bladder, ovary, uterine, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage including leukaemia, T and B acute lymphoblastic leukemia (ALL), including DS-ALL, B-cell lymphoma, T-cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, Multiple Myeloma, hairy cell lymphoma, Burkett's lymphoma and mantle cell lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, acute megakaryoblastic leukemia, myelodysplastic syndrome and promyelocytic leukemia, myeloproliferative disorders like Polycythemia Vera (PV), Essential Thrombocythemia (ET), Primary myelofibrosis and myelofibrosis secondary to PV and ET, chronic myelomonocytic leukemia; tumors of mesenchymal origin, including sarcoma, fibrosarcoma and rhabdomyosarcoma; tumors of the central and peripheral nervous system, including astrocytoma neuroblastoma, glioma and schwannomas; other tumors, including melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoxanthoma, thyroid follicular cancer, Kaposi's sarcoma, mesothelioma.

### Claim 42 (depends on 40)

The method according to claim 40 wherein the cell proliferative disorder is selected from the group consisting of benign prostate hyperplasia, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis, glomerulonephritis and post-surgical stenosis and restenosis.

### Claim 43 (depends on 40)

The method according to claim 40 wherein the immune-related disorder is selected from the group consisting of transplant rejection, skin disorders like psoriasis, allergies, asthma and autoimmune-mediated diseases such as rheumatoid arthritis (RA), multiple sclerosis, systemic lupus erythematosus (SLE), Crohn's disease and amyotrophic lateral sclerosis.

### Claim 44 (depends on 40)

The method according to claim 40 wherein the neurodegenerative disorder is selected from the group consisting of Alzheimer's disease, degenerative nerve diseases, encephalitis, Stroke, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Huntington's Disease, Pick's Disease.

### Claim 45 (depends on 40)

The method according to claim 40 wherein the cardiovascular disease is selected from the group consisting of atherosclerosis primary or secondary to diabetes, heart attack and stroke.

### Claim 46 (depends on 40)

The method according to claim 40 further comprising subjecting the mammal in need thereof to a radiation therapy or chemotherapy regimen in combination with at least one cytostatic or cytotoxic agent.

### Claim 47 (depends on 31)

A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined in claim 31, and at least one pharmaceutically acceptable excipient, carrier and/or diluent.

### Claim 48 (depends on 47)

A pharmaceutical composition, according to claim 47, further comprising one or more chemotherapeutic agents.

### Claim 49 (depends on 31)

An in vitro method for inhibiting the JAK family kinase proteins activity which comprises contacting the said protein with an effective amount of a compound of formula (I) as defined in claim 31.

### Claim 50 (depends on 31)

A product comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined in claim 31, and one or more chemotherapeutic agents, as a combined preparation for simultaneous, separate or sequential use in anticancer therapy.
